Auriga Partners

Entomed

Availpro SAS develops and delivers e-booking software solutions that allow hotels to increase their occupancy and revenue. It offers Smart Booking Engine, a solution to increase sales on website; Facebook Booking Engine, a solution to boost hotel’s social sales and promote special offers; Mobile Booking Engine, a solution to make mobile sales a reality; Smart Channel Manager, a solution to manage availability rooms and rates with a single planner; and PMS/CRS connectivity, a solution to convert availability into bookings. The company also provides GDS connectivity, a solution to sell rooms directly through travel agencies; RateScreener/Parity Checker, a solution to analyze and compare competitors’ rates; NextRate, a solution to optimize and sell at the right price; Guest Reviews, a solution to improve guest satisfaction; and Sentinel, a solution to monitor and analyze hotel’s online reputation. It serves independent hotels, hotel chains and hotel groups, and aparthotels. Availpro SAS was formerly known as Siriona S.A. The company was founded in 2001 and is based in Paris, France with sales offices in Europe. As of April 5, 2017, Availpro SAS operates as a subsidiary of Accor SA.

Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies.

MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.

ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.

SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

Aquarelle operates as an online florist. It offers scented seasonal bouquets for birthdays, births, weddings, and other occasions; indoor and outdoor decorations for gardens, terraces, patios, and others; and flowers, chocolates, confectionery, fruits or woodland berries, and fragrance compositions. The company operates stores in Paris and Rennes, France. It delivers products to customers in France, the United States, the United Kingdom, Canada, Australia, Ireland, India, and internationally. Aquarelle was founded in 1987 and is based in Paris, France.

EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.

They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

Nemoptic, an epaper display company, designs and manufactures superior-quality bistable liquid crystal displays (LCD) modules highly suitable for consumer and professional mobile devices.

Pherecydes Pharma SA engages in the research and development of lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance. It develops several banks of bacteriophages, including the collection of phages against Escherichia coli. The company was incorporated in 2006 and is based in Romainville, France.

TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Neolane, Inc. is a conversational marketing technology provider, which develops marketing automation and cross-channel campaign management software and services for business-to-business and business-to-consumer marketers. In 2012, Neolane recorded $58 million in revenue representing 40% year-over-year growth. In 2013, Neolane was named #64 on the Forbes list of America's Most Promising companies. Neolane provides the only conversational marketing technology that empowers organizations to build and sustain one-to-one lifetime dialogues, dramatically increasing revenue and marketing efficiency. Neolane has a track record of enabling its customers to adapt to new customer engagement challenges and exploit opportunities more quickly than their competition. Neolane is used by more than 400 of the world's leading companies including Alcatel Lucent, barnesandnoble.com, Orange, Sears Canada, Sephora Europe, and Sony Music.

Miliboo Société anonyme designs and provides furniture. The company offers sofas and armchairs, bar stools, desk and office chairs, tables, storage furniture, bathroom furniture, decor furniture, garden furniture, and table lamps, as well as furniture for children. Miliboo Société anonyme was founded in 2005 and is based in Paris, France.

GliSODin Skin Nutrients is a professional medical line of nutricosmetics focused on optimal internal support. It provides the skin with essential nutrients and functions to protect it from the effects of oxidative stress. GliSODin Skin Nutrients was founded in 2008 and is based in Paris, France.

Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. They develop, manufacture, and distribute products that make cellular analysis robust and reliable by dramatically decreasing cell variability. There new micropattern-based products are designed to meet the needs of all clients whatever their research goals. They are open to suggestions or specific requests that can improve and spread the scope of this breakthrough in quantitative cell analysis.

AlchiMedics is focused on the implementation of electro-grafting technology for implantable biomedical applications. Its technology is used for fast healing post drug-eluting-stent implantation procedures. AlchiMedics was founded in 2007 and is based in Massy, France.

aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

Bonitasoft fully supports digital operations and IT modernization with Bonita, an open-source and extensible platform for automation and optimization of business processes. The Bonita platform accelerates development and production with clear separation between capabilities for visual programming and for coding. Bonita integrates with existing information systems, orchestrates heterogeneous systems, and provides deep visibility into processes across the organization.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Amoeba is focused on developing and commercializing green biocide water treatment chemicals. It offers BIOMEBA, a green biocide that harnesses the biocidal properties of Willaertia magna to treat the bacterial risks encountered in cooling towers.

Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Milagen is developing and commercializing innovative products to improve the quality of life of patients suffering from cancer. For many years the company has been engaged in research and development to provide innovative proprietary products for surveillance and monitoring of major cancers. Currently, Milagen manufactures and commercializes tissue-based immunodiagnostic products as an aid to the pathologist. It also offers its product line directly to end-users, and in partnership with diagnostic companies and clinical reference laboratories. Milagen

Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company’s lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.

Pherecydes Pharma SA engages in the research and development of lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance. It develops several banks of bacteriophages, including the collection of phages against Escherichia coli. The company was incorporated in 2006 and is based in Romainville, France.

aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

Spine Next is a biotech company that manufactures and markets orthopedic spinal implant devices for spinal fusion surgeries. Spine Next is a France-based company that was founded in 1999 and the company was acquired by Abbott on October 25, 2004.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

Nemoptic, an epaper display company, designs and manufactures superior-quality bistable liquid crystal displays (LCD) modules highly suitable for consumer and professional mobile devices.

At Santen, they’re innovating therapies to improve the quality of life for patients worldwide. Their single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Their clinical development network now spans three continents, with centers in Europe, Japan, and the United States.

Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases.

SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

Founded in 2009 in Lyon, France and located and member of LyonBiopôle cluster, Fab’entech is a biopharmaceutical company which develops and commercializes a range of innovative passive immunotherapeutic solutions based on specific polyclonal immunoglobulins [F(ab’)₂] in the field of emerging infectious diseases, as well as for certain drug intoxications.

aveni, Inc. provides metallization technologies for damascene through silicon vias, MEMS, and other electronic applications. Its portfolio includes Electrografting (eG), a wet electrochemical-based process that enables the growth of extremely high-quality thin films of various types on conducting and semiconducting surfaces; and Chemicalgrafting (cG), which is used on non-conductive substrates. The company’s eG and cG processes are implemented on hardware platforms or run on tools ranging from wet benches to automated systems. It serves semiconductor and renewable energy companies worldwide. aveni, Inc. was formerly known as Alchimer S.A. The company was founded in 2001 and is based in Massy, France.

Milagen is developing and commercializing innovative products to improve the quality of life of patients suffering from cancer. For many years the company has been engaged in research and development to provide innovative proprietary products for surveillance and monitoring of major cancers. Currently, Milagen manufactures and commercializes tissue-based immunodiagnostic products as an aid to the pathologist. It also offers its product line directly to end-users, and in partnership with diagnostic companies and clinical reference laboratories. Milagen

QantEv SAS develops an Artificial intelligence solution to get insight from historical claims data to make data driven decisions and build an impactful business strategy. The company was founded in 2019 and is based in Paris, France.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Streamcore is a leading provider of visibility and dynamic performance control solutions for managing interactive applications and real-time communications (VoIP, video…) delivery over the WAN. Streamcore products enable enterprises to benefit from all-in-one visibility - network, applications, VoIP, video -, real-time monitoring and advanced on-demand reporting from a single centralized management console. What makes Streamcore solutions unique is that visibility and advanced performance control are tied together and can be enabled from data centers to ensure fast deployment and cost-efficiency.

MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.

Oxand is an international consulting and solutions provider with proven capabilities, knowledge and tools for capital intensive assets. As an independent company, they deliver risk-informed decision support information that improves returns across the life cycle of their clients’ assets. Their worldwide clients are investors, owners, contractors and managers in Energy (Nuclear, Oil & Gas, Renewables), Transport (Railways, Roads & Waterways) and Public/Private Properties (Public Infrastructures, Private & Industrial assets). Enhancing their clients’ reputations by supporting better decisions, with more than 1,150 billion Euros worth of analysed assets, they have experience that includes optimising the life cycle decisions and reducing costs by 10 to 30%; making possible life extension versus renewals; and reducing costly delays of large projects. Their solutions, supported by their Simeo™ technologies and data libraries, are fully compliant with best standards (as ISO 55000, ISO 31000, ISO 15288, NEC3…). They deliver tailored consultancy, training and IT solutions.

SpinX develops and commercializes a programmable lab-on-a-chip platform for applications that ranges from drug discovery to consumer diagnostics. Its products include SpinX Lab, a system to transition from low volume microplate assays to an automated bench-top technology for assays in nanoliter volumes; and workflow, an assay preparation for a panel of enzymatic assays. Bart Van de Vyver and Piero Zucchelli founded SpinX in 2003. It has its headquarters in Geneva in Switzerland.

Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Theradiag is a France-based company which develops and markets biological diagnostic tools. The company develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases.

Neolane, Inc. is a conversational marketing technology provider, which develops marketing automation and cross-channel campaign management software and services for business-to-business and business-to-consumer marketers. In 2012, Neolane recorded $58 million in revenue representing 40% year-over-year growth. In 2013, Neolane was named #64 on the Forbes list of America's Most Promising companies. Neolane provides the only conversational marketing technology that empowers organizations to build and sustain one-to-one lifetime dialogues, dramatically increasing revenue and marketing efficiency. Neolane has a track record of enabling its customers to adapt to new customer engagement challenges and exploit opportunities more quickly than their competition. Neolane is used by more than 400 of the world's leading companies including Alcatel Lucent, barnesandnoble.com, Orange, Sears Canada, Sephora Europe, and Sony Music.

Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.

Eptica S.A. designs and develops customer relationship management (CRM) software for business-to-business (B2B) marketplaces. The company’s solutions help enterprises to develop and manage real-time relationship with clients, suppliers, and partners via the Internet. It also provides technical support, training, as well as consulting. Eptica S.A. serves banking, insurance, retail, tourism, and public institutions sectors. The company was founded in 2001 and is based in Boulogne-Billancourt, France. As of October 22, 2019, Eptica S.A. operates as a subsidiary of Enghouse Systems Limited.

eXo Platform (https://www.exoplatform.com) is an open source social collaboration platform that is highly extensible and based on open standards. With eXo you can not only build an enterprise social network, but you can also build a website, a social intranet or a community website. Hundreds of large organizations—in sectors ranging from government and financial services to telecom—use eXo products today, as do thousands of enterprises in other sectors through the company’s strategic partnership with Red Hat. eXo operates globally and has offices in the United States, France, Tunisia, Ukraine and Vietnam.

Firalis SAS, engages in the discovery and development of biomarker-based diagnostics. It offers inflammatory biomarkers; peripheral bio-markers for the early diagnosis of minimal vasculitis in humans; and diagnostic kits for early prediction of coxibs associated cardiovascular risks. The company’s portfolio also includes biomarkers for early kidney injuries and liver functions. In addition, it offers biomarker research and development strategy design, biomarker discovery and qualification, biomarker assay development and validation, sample testing, and integrative data analysis services. Firalis SAS was founded in 2008 and is based in Huningue, France.

At Santen, they’re innovating therapies to improve the quality of life for patients worldwide. Their single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Their clinical development network now spans three continents, with centers in Europe, Japan, and the United States.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

VitaDX is a startup applying artificial intelligence to the healthcare sector, and more specifically to the early diagnosis of cancer by exploiting fluorescence imaging in favor of a first product, VisioCyt®, dedicated to the detection of cancer of the bladder. This solution will allow the diagnosis of bladder cancer from a simple urine sample to improve the performance of urinary cytology conventionally used in first intention.

Bonitasoft fully supports digital operations and IT modernization with Bonita, an open-source and extensible platform for automation and optimization of business processes. The Bonita platform accelerates development and production with clear separation between capabilities for visual programming and for coding. Bonita integrates with existing information systems, orchestrates heterogeneous systems, and provides deep visibility into processes across the organization.

Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.

Bag Tech develops, designs, and manufactures a variety of bags.

Codenvy is a provider of a cloud development platform designed for coding, building and testing applications.The company's cloud development environment takes the local desktop workspace, which consists of the editor, builder and tester runtimes and separates it logically from its underlying physical environment and moves it into the cloud, enabling enterprises to access workspaces that are on-demand, collaborative and constraint-free.

MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. The company standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN Technologies has a strategic partnership with a contract research organization to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market. MEDIAN Technologies was founded in 2002 and is based in Sophia-Antipolis, France.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Honing Biosciences SAS, a bio-therapeutics company, develops and improves cell-based therapies to treat cancer and other chronic diseases. It offers molecular CellTuneTM technology that allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. The company offers therapies, such as CAR-T (chimeric antigen receptor T) cells therapy to kill cancer cells and Checkpoint inhibitors, a technology allowing to select small antibodies (nanobodies) based on proprietary scaffold, which they can deliver intracellularly. Its technology regulates protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, and adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences SAS was incorporated in 2018 and is based in Paris, France.

Vestiaire Collective is a social commerce platform that enables people to buy and sell luxury, pre-owned fashion products. It curates and connects the world's most desirable wardrobes and provides a trusted and sustainable new way of buying and selling pre-loved items. Founded in 2009, Vestiaire Collective has over 7.5 million fashion savvy members in 50 countries worldwide. Every week, over 30,000 new items are submitted by its community of sellers, enabling buyers to access over 3,500 coveted and must have fashion pieces a day. Vestiaire Collective is based in Paris with offices in London, New York, Milan, Berlin, and Hong Kong.

At Santen, they’re innovating therapies to improve the quality of life for patients worldwide. Their single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Their clinical development network now spans three continents, with centers in Europe, Japan, and the United States.

SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

Bag Tech develops, designs, and manufactures a variety of bags.

Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.

AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Aqemia SAS develops drug discovery software that predicts the affinity between drug candidates and therapeutic targets responsible for diseases. The company was founded in 2019 and is based in Paris, France.

Nemoptic, an epaper display company, designs and manufactures superior-quality bistable liquid crystal displays (LCD) modules highly suitable for consumer and professional mobile devices.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Bonitasoft fully supports digital operations and IT modernization with Bonita, an open-source and extensible platform for automation and optimization of business processes. The Bonita platform accelerates development and production with clear separation between capabilities for visual programming and for coding. Bonita integrates with existing information systems, orchestrates heterogeneous systems, and provides deep visibility into processes across the organization.

Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Bag Tech develops, designs, and manufactures a variety of bags.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Biolipox is a research-intense pharmaceutical company that develops treatments for inflammatory diseases. This includes widespread diseases such as asthma, COPD, rhinitis, and inflammatory and rheumatic pain. The company offers its users with current arachidonic acid research. Arachidonic acid is an endogenous substance that plays a central role in the development of inflammatory diseases. It is an established research area that empowers several drugs such as Aspirin, Naproxen, and Singulair. Biolipox is a Sweden-based company that was founded in 2000 and the company was acquired by Orexo on November 23, 2007.

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.